7MCK
Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 18
Summary for 7MCK
Entry DOI | 10.2210/pdb7mck/pdb |
Descriptor | Serine/threonine-protein kinase Chk1, N-{5-[(3S)-3-(2-hydroxypropan-2-yl)pyrrolidin-1-yl]-2-(trifluoromethyl)pyridin-3-yl}-6-(1-methyl-1H-pyrazol-4-yl)pyridine-2-carboxamide (3 entities in total) |
Functional Keywords | kinase, parkinsons disease, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 34568.69 |
Authors | Palte, R. (deposition date: 2021-04-02, release date: 2021-06-16, Last modification date: 2023-10-18) |
Primary citation | Gulati, A.,Yeung, C.S.,Lapointe, B.,Kattar, S.D.,Gunaydin, H.,Scott, J.D.,Childers, K.K.,Methot, J.L.,Simov, V.,Kurukulasuriya, R.,Pio, B.,Morriello, G.J.,Liu, P.,Tang, H.,Neelamkavil, S.,Wood, H.B.,Rada, V.L.,Ardolino, M.J.,Yan, X.C.,Palte, R.,Otte, K.,Faltus, R.,Woodhouse, J.,Hegde, L.G.,Ciaccio, P.,Minnihan, E.C.,DiMauro, E.F.,Fell, M.J.,Fuller, P.H.,Ellis, J.M. Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors. Rsc Med Chem, 12:1164-1173, 2021 Cited by PubMed: 34355182DOI: 10.1039/d1md00097g PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.65 Å) |
Structure validation
Download full validation report